Moderna's Comeback and Biotech Risks

Cramer outlines Moderna's rebound, potential vaccine and cancer prospects, and why it's still unprofitable long-term.

Play episode from 17:00

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!